Molecular mechanisms and mode of tamoxifen resistance in breast cancer.
Molecular mechanisms and mode of tamoxifen resistance in breast cancer.
复制标题
他莫昔芬在乳腺癌中的分子机制和模式。
DOI：
10.6026/97320630012135
复制
发表时间：
2016
期刊：
影响因子：
1.9
通讯作者：
Sarwar Jamal M
中科院分区：
文献类型：
--
作者：
Ali S;Rasool M;Chaoudhry H;N Pushparaj P;Jha P;Hafiz A;Mahfooz M;Abdus Sami G;Azhar Kamal M;Bashir S;Ali A;Sarwar Jamal M
乳腺癌是全球女性最常见的癌症之一，在过去的40年里，三苯氧胺一直被用作乳腺癌的内分泌疗法。这使得死亡率降低了30%，它仍然是治疗乳腺癌最有效的疗法之一。然而，对他莫昔芬的耐药性仍然是乳腺癌有效治疗的主要障碍之一。在过去的十年里，人们进行了密集的研究，以进一步探索其抗性机制，但仍需进行大量研究，以有效缓解这一问题。一些生化因素和分子途径，如ER信号的调节、生长因子的上调等，已被观察到是三苯氧胺耐药的关键因素。经过五到十年的初步治疗，乳腺癌患者对这种药物产生抗药性。这种耐药性会导致其他癌症的发展，如子宫癌。在这里，我们简要地探讨与他莫昔芬耐药相关的所有分子事件，并重点介绍其作用机制以及其他药理学方法，以更好地发挥其在乳腺癌治疗中的有利作用。
Breast cancer is one of the most common cancers in women around the globe Tamoxifen is used for the last 40 years as an endocrine therapy for breast cancer. This resulted in the reduction of mortality rate by 30% and it still remains one of the most effective therapies against breast cancer. However, resistance against tamoxifen is still one of the major hurdles in the effective management of breast cancer. Intense research has been conducted in the past decade to further explore its resistance mechanism, but still a lot of research will be needed to effectively alleviate this problem. Several biochemical factors and molecular pathways, such as the modulation of ER signaling, upregulation of growth factors had been observed as key factors for tamoxifen resistance (TR). After, initial therapy of five to ten years, breast cancer patients develops resistance towards this drug. The resistance leads to the development of other cancers like uterine cancer. Here, we briefly explore all the molecular events related to tamoxifen resistance and focus on its mechanism of action as well as other pharmacological approaches to better its beneficial effects in the treatment of breast carcinoma.